

Index of Contributors

Abdel-Malek, Z., 508-510

Adams, G., 440-441

Affholter, J. A., 597-599

Ahmed, A. R. H., 442-444

Al-Obeidi, F., 51-63

Albert, R., 445-447

Alessandrini, G., 502-504

Alves, S. E., 29-50

Ambrogio, C., 558-560, 561-563

Ansel, J., 567-570

Antonawich, F. J., 29-50

Azrad, A., 364-380

Bagasra, O., 575-578

Bagutti, C., 320-341, 445-447

Bahjaoui, M., 511-516

Baker, B. I., 279-289, 489-492

Balm, P. H. M., 448-450

Bär, P. R., 533-535, 649-651

Barberis, A. M., 561-563

Bard, D. R., 451-453

Battie, C. N., 575-578

Beatty, D. M., 579-584

Bergasa, N. V., 454-458

Biaggi, M. H., 459-461

Bickford, P. C., 571-574

Bittencourt, J. C., 462-465

Blasquez, C., 260-278, 466-469

Bloomquist, B. T., 147-160

Bodkin, N. L., 585-587

Boeri, E., 558-560, 561-563

Botyánszki, J., 616-618

Branch, S. K., 440-441, 442-444, 517-519

Bresson, J. L., 511-516

Breton, C., 111-129

Bruns, C., 445-447

Bugnon, C., 511-516

Calvelli, P., 561-563

Cao, V. A., 302-319

Cardot, J., 511-516

Castrucci, A. M. L., 459-461, 597-599

Catania, A., 412-423

Cazin, L., 211-228, 564-566

Celis, M. E., 591-593, 594-596

Charli, J-L., 505-507

Chartrel, N., 175-187, 470-471, 626-629

Chatikhine, V. A., 473-475

Chauveau, I., 476-477

Chauzy, C., 473-475

Chen, X-W., 545-548

Chevrier, A., 473-475

Chhajlani, V., 320-341

Chluba-de Tapia, J., 320-341, 660-662

Chrétien, M., 13-19, 135-146

Chronwall, B. M., 478-480, 579-584

Ciranna, L., 199-210

Clavequin, M. C., 511-516

Compagnone, N., 511-516

Cone, R. D., 342-363

Conlon, J. M., 626-629

Corn, T. D., 302-319

Cremer, C., 591-593

Cresswell, J. E., 549-551

Crujisen, P. M. J. M., 188-198

D'Alessandro, V., 558-560

d'Aniou, J., 473-475

Darlington, C. L., 481-482, 524-526

Davenport, M., 585-587

Davies, D. A., 483-485

Day, R., 135-146

de Koning, H. P., 188-198

de Rijk, E. P. C. T., 486-488

de Wied, D., 20-28

de Barioglio, S. R., 591-593, 594-596

De Gennaro, T., 558-560

De Vaux, A. E., 597-599

De Loof, A., 600-602

Degani, H., 364-380

Deguchi, Y., 609-611

Dejordy, J. O., 364-380

Delbende, C., 260-278, 630-633

Delpech, B., 473-475

Desrués, L., 175-187, 188-198, 520-523

Dickerson, D. S., 478-480

Donatien, P. D., 381-390, 549-551

Dores, R. M., 161-174, 530-532, 612-615

Dorr, R. T., 424-439

Douglas, W. W., 229-245, 606-608

Drouin, J., 663-671

Drozdz, R., 489-492

Duckers, H. J., 493-495

Dunmore, S., 499-501

Duval, C., 473-475

Dyer, J. K., 496-498

Eagle, L., 499-501

Eberle, A. N., xv, 320-341, 445-447,

489-492, 652-654, 660-662

Eipper, B. A., 147-160

Elias, C. F., 462-465

Eshel, Y., 364-380

Evans, V. R., 575-578

- F**acchinetti, F., 502-504
 Faivre-Bauman, A., 505-507
 Farooqui, J. Z., 508-510
 Félix, J. M., 89-110, 643-645
 Fellmann, D., 511-516
 Feltz, P., 199-210
 Forman, L. J., 575-578
 Forsyth, G., 517-519
 Fournier, A., 466-469
 Fuller, B. B., 302-319
- G**allinelli, A., 502-504
 Garnier, M., 520-523
 Garty, N. B., 364-380
 Gary, K. A., 478-480
 Ghanem, G. E., 391-400, 616-618, 655-659
 Giesecke, K. E., 530-532
 Gilchrist, D. P. D., 481-482, 524-526
 Gispén, W. H., 401-411, 493-495, 533-535, 649-651
 González de Aguilar, J. L., 527-529
 Gouget, A., 511-516
 Gracia-Navarro, F., 527-529
 Gröneveld, D., 448-450
- H**adley, M. E., 51-63, 424-439, 597-599
 Halaban, R., 290-301
 Hanimann, B., 652-654
 Hansen, B. C., 585-587
 Hayashi, H., 552-554
 Haynes, L. W., 496-498
 Hemet, J., 555-557
 Hervieu, G., 111-129
 Hindelang, C., 89-110
 Hoganson, G. E., 302-319
 Hol, E. M., 533-535
 Hruby, V. J., 51-63, 424-439, 571-574, 597-599
 Hughes, S., 536-538, 539-541, 542-544
 Humphreys, M. H., 545-548
 Hunt, G., 381-390, 549-551
 Husten, E. J., 147-160
- I**ozumi, K., 302-319
 Itoi, K., 619-620
 Iwamuro, S., 552-554
- J**aw, J. Y., 51-63
 Jégo, P., 476-477
 Jégou, S., 260-278, 466-469, 555-557, 600-602
 Jenks, B. G., 130-134, 175-187, 188-198, 603-605, 639-642
 Johnson, K. R., 342-363
 Jones, E. A., 454-458
- K**awauchi, H., 64-77, 619-620
 Kikuyama, S., 552-554
 Klein, M. J., 89-110
 Knight, C. G., 451-453
 Kondo, S., 609-611
 Kordon, C., 505-507
 Krutmann, J., 567-570
- L**amacz, M., 175-187, 470-472, 520-523
 Lamers, A. E., 448-450
 Lamy-Freund, M. T., 459-461
 Laquerrière, A., 555-557
 Lee, S. J., 29-50
 Lee, T. S., 29-50
 Leiba, H., 364-380
 Lejeune, F. J., 391-400, 655-659
 Lenys, D., 511-516
 Lerner, A. B., 1-12
 Lespagnard, L., 655-659
 Levine, N., 424-439
 Lezcano, N. E., 594-596
 Libert, A., 616-618
 Lichtensteiger, W., 652-654
 Liénard, D., 655-659
 Limone, P., 558-560, 561-563
 Lipton, J. M., 412-423
 Loh, P. Y., 454-458
 Loudes, C., 505-507
 Louiset, E., 520-523, 564-566
 Luger, T. A., 567-570
- M**ains, R. E., 147-160
 Mandys, V., 649-651
 Marcinkiewicz, M., 135-146
 Martens, G. J. M., 130-134
 Matsumoto, T., 609-611
 Matsunaga, T. O., 571-574
 Matsunoto, S., 600-601
 Mauger, C. M. A., 188-198
 Mbikay, M., 13-19
 Medrano, E. E., 508-510
 Medzihradsky, K., 616-618
 Milgram, S. L., 147-160
 Miller, C. L., 571-574
 Millington, W. R., 575-578
 Molinatti, G. M., 558-560, 561-563
 Morandini, R., 616-618
 Morris, S. J., 579-584
 Morton, J., 499-501, 585-587
 Mortrud, M. T., 342-363
 Moss, S. H., 440-441, 442-444, 517-519
 Mouginot, D., 199-210
 Mountjoy, K. G., 342-363
 Mouri, T., 619-620
 Murakami, O., 619-620

- N**adeau, J. H., 342-363
 Nahon, J.-L., 111-129
 Naito, N., 64-77
 Neri, I., 502-504
 Nomizu, M., 552-554
 Nordlund, J., 508-510
 Notarianni, L. J., 440-441, 442-444, 517-519
- O**hneda, M., 619-620
 Olivier, G. W. J., 440-441, 442-444
 Ono, M., 64-77
 Osguthorpe, D., 517-519
 Owens, K. C., 302-319
- P**arkes, D. G., 588-590
 Pelletier, G., 246-259
 Peulve, P., 555-557
 Philipsen, H. L. A., 496-498
 Plante, M., 89-110
 Pless, J., 445-447
 Polzonetti-Magni, A., 502-504
 Pouton, C. W., 440-441, 442-444, 517-519
 Presse, F., 111-129
 Price, M. L., 161-174
- R**ainero, I., 558-560
 Ramadan, S. T., 302-319
 Rao, K. R., 78-88
 René, F., 89-110, 643-645
 Riehm, J. P., 78-88
 Risold, P. Y., 511-516
 Robbins, L. S., 342-363
 Roselli-Rehfuß, L., 342-363
 Roubos, E. W., 130-134, 188-198, 486-488, 603-605, 639-642
 Rubin, J., 290-301
 Rungta, D., 302-319
- S**albert, G., 476-477
 Salomon, Y., 364-380
 Sasano, H., 619-620
 Sasano, N., 619-620
 Sawyer, T. K., 51-63, 597-599
 Scaglione, E., 561-563
 Schauer, E., 567-570
 Scheenen, W. J. J. M., 603-605
 Schlichter, R., 199-210
 Schlumpf, M., 652-654
 Schmidt-Sole, J., 364-380
 Schoofs, L., 600-602
 Schorpp, M., 111-129
 Schreier, S., 459-461
 Schwarz, A., 567-570
 Schwarz, T., 567-570
- Scipioni, T., 561-563
 Seidah, N. G., 13-19, 135-146
 Shafir, I., 364-380
 Shai, E., 364-380
 Sharma, S. D., 51-63, 424-439
 Shibuya, I., 229-245, 606-608
 Shimura, T., 609-611
 Sibley, D. R., 478-480
 Siegrist, W., 320-341, 652-654
 Smeets, W. J. A. J., 486-488
 Smith, M. E., 483-485, 536-538, 539-541, 542-544
 Smith, P. F., 481-482, 524-526
 Solca, F., 320-341
 Sone, M., 619-620
 Staples, D. J., 597-599
 Steveson, T. C., 161-174, 612-615
 Stoeckel, M. E., 89-110, 643-645
 Stolz, B., 445-447
 Strand, F. L., 29-50
 Sugihara, S., 552-554
 Süli-Vargha, H., 616-618
- T**abata, S., 609-611
 Tadie, M., 555-557
 Takahashi, K., 619-620
 Tanaka, S., 552-554
 Tatro, J. B., 621-625
 Terasaki, T., 609-611
 Therrien, M., 663-671
 Thody, A. J., 381-390, 549-551
 Todd, C., 381-390
 Tonnaer, J. A. D. M., 496-498
 Tonon, M. C., 175-187, 188-198, 470-472, 520-523, 527-529, 626-629
 Toth, K., 51-63
 Totsune, K., 619-620
 Tranchand Bunel, D., 260-278, 466-469, 476-477, 626-629, 630-633, 634-638
 Trautinger, F., 567-570
 Tsuda, S., 609-611
 Tsuji, A., 609-611
 Tuinhof, R., 486-488
 Tureček, R., 649-651
 Turner, M. L., 454-458
 Tyrrell, L., 290-301
- V**adoud Seyedi, J., 655-659
 Vale, W. W., 588-590
 Valentijn, J. A., 211-228
 Valentin, J.-P., 545-548
 Vallarino, M., 502-504, 630-633, 634-638
 Valotaire, Y., 476-477
 van Strien, F. J. C., 639-642
 Van Essen, E. H. R., 533-535
 Van Wijck, R., 655-659

Vaudry, H., xv, 175-187, 188-198,
211-228, 260-278, 466-469, 470-472,
476-477, 520-523, 527-529, 555-557,
564-566, 600-602, 626-629, 630-633,
634-638

Vergalla, J., 454-458

Verhaagen, J., 493-495

Vuillez, P., 89-110, 643-645

Wayman, C. P., 646-648

Wendelaar Bonga, S. E., 448-450

Wiedemann, E., 545-548

Wikberg, J. E. S., 320-341

Willems, P. H. G. M., 603-605

Williams, K. A., 29-50

Wilson, J. F., 646-648

Wismans, R. G. P., 486-488

Wraight, E. P., 452-453

Yarden, Y., 290-301

Ying, W.-Z., 545-548

Yun, J., 555-557

Zeller, A., 489-492

Zohar, M., 364-380

Zuccarelli, L. A., 29-50

Subject Index

- A** acetylation mechanism
of POMC end products, 162-172
POMC-specific, 161-162
- Acetylcholine (ACh)
calcium signals and, 229
and MCH gene expression, 514
in α -MSH secretion, 471
- Acetylcholine (ACh) release, POMC
derivatives and, 483-484
- ACTH**
analogues, *see* BIM 22015; ORG2766
biological activities of 342, 344, 346-348,
364-365
 Ca^{2+} dependency of, 365
cAMP stimulation by, 376-377
in cardiac muscle, 575-577
diabetes mellitus and, 542-544
distribution of, 20
fragments, *see* ACTH peptides
melanotropinlike activity of, 51
neuromodulatory role of, 33-35
in neuropathy treatment, 401-402, 405-408
pathology involving, 344, 346
in PBC, 454
in peripheral nerve regeneration, 31
in postlesion neuron repair, 403-404
receptors, 344, 346
characterization of, 355-359
cloning of, 347-352
in skeletal muscle, 542-544
release
MCH in, 73
melanotropic peptides and, 483-484
and sexual dimorphic behavior, 46
- ACTH peptides**
and ACh release, 483-484
antipyretic effect of, 25
and avoidance behavior, 20
in CNS regeneration, 31, 33-36
and DA fiber density, 35
distribution of, 20-21
formation of, 21
and grooming behavior, 22
and 5-HT innervation, 35
5-HT system modulation by, 31, 33-35
and learning, 25
and motor function recovery, 38-48
and MVN neurons, 481-482
in nerve regeneration, 31, 47
in neurite growth, 32, 46
neuroactivity of, 21
in neuromuscular maturation, 29, 31, 36-37
in peripheral nerve regeneration, 31
POMC processing and, 29
receptors of, 21, 26
and spontaneous nystagmus compensation,
524-526
structure of, 30
- Action potential, *see also* Membrane potential
 Ca^{2+} and, 229-231
DA suppression of, 214-215
GABA inhibition of, 564
in melanotrophs, 230
in melanotroph secretion, 211
 Na^+ and, 230
TRH acceleration of, 230
- Addison's disease, 434, 437
- Adenofibromas, β end expression in, 473-474
- Adenosine, in α -MSH release, 470-472
- Adipokinetic hormone (AKH), 79-80
- Adrenergic system, and α -MSH secretion,
558-560
- Age**
and ACTH-induced grooming, 23
and ORG2766-influenced behavior, 25
- AIDS, α -MSH treatment potential in, 418-419
- Allgrove's syndrome, 346
- γ -Aminobutyric acid (GABA)
in action potential suppression, 214-215
and $[Ca^{2+}]_i$, 232
and $[Ca^{2+}]_i$ pulsing, 238, 606-608
and Cl^- current inhibition, 564-566
DA colocalization with, 199, 486
and melanotroph secretoinhibition, 130-132,
234-235
and α -MSH induced behavior, 591-593
 α -MSH inhibition by, 130-131, 176-178,
183, 188
in α -MSH neuron regulation, 267-270
NPY colocalization with, 177, 486
and POMC gene expression, 89
receptors
 $[Ca^{2+}]_i$ modulation of, 200-205
in α -MSH release, 199
- Amphetamine**
behavioral effects of, 42
- Antipyretic action**
of ACTH peptides, 25
of melanotropins, 25-26
of α -MSH, 25, 412-415, 418
- Antisense DNA**, GF inhibition by, 16
- Apomorphine**
behavioral effects of, 42
- Arginine vasopressin (AVP) secretion**,
588-590
- ATP depletion**, in melanoma cells, 370-373
- Auditory gating**, α -MSH-MCH antagonism
and, 571-574

Avoidance behavior, ACTH/MSH neuropeptides and, 22

Background adaptation

DA in, 486–487
inositol phosphate metabolism in, 188–197
melanotrophs in, 639

Baclofen

and $[Ca^{2+}]_i$, 232
and α -MSH-induced behavior, 591–593

Basic fibroblast growth factor (bFGF)

in melanocyte differentiation, 292–293
in melanocyte proliferation, 293–295
in melanoma cells, 292
and nerve regeneration, 555–556

BCT, *see* Beta-cell tropin (BCT)

Behavior, ACTH/MSH neuropeptides and, 22–26

Beta-cell tropin (BCT) secretion

DA effect on, 499–500
and obesity, 585–586

bFGF, *see* Basic fibroblast growth factor
BIM 22015

and motor function recovery, 38–40
and neurite growth, 32, 34, 46–47
and neuromuscular maturation, 29, 31
structure of, 30

bisMSH-DPTA, *see also* Melanocyte-stimulating hormone

in melanoma imaging, 451–453
in MSH receptor detection, 445–447

Brain-derived neurotrophic factor (BDNF), 32

Breast cancer, β end expression in, 473–474

Ca^{2+}

and action potential, 229–231
in α -MSH release, 180–181, 274
and secretion, 234, 241–242

Ca^{2+} channel

gating

DA control of, 211–226, 233–234
DA D_2 receptors in, 212–221
G protein role in, 212–223, 225–226
 K^+ channels in, 212–219
 Na^+ channels in, 219–221
voltage-activated, 211–212

Ca^{2+} currents

DA inhibition of, 199
5-HT modulation of, 200, 205–208

$[Ca^{2+}]_i$

baclofen and, 235
DA and, 235
GABA-receptor modulation by, 199–200
imaging of, 579–584
and melanotroph secretion, 234

nicotine effect on, 521–522

and secretion relationships, 241

$[Ca^{2+}]_i$ pulsing, 237–241

cAMP and, 240, 606–608

channel-blocker effects on, 603–606

neuropeptide suppression of, 606–608

secretoinhibitory neurotransmitters and, 238

Calcium oscillation, *see* $[Ca^{2+}]_i$ pulsing

Calcium signals, 229–231

Calmodulin-binding peptides (CBPs), in melanoma cells, 367–369

cAMP

ACTH stimulation of, 376–377

and $[Ca^{2+}]_i$ pulsing, 240, 606–608

"cAMP-sink" mechanism, 372–373

in melanocyte differentiation, 290, 294

in melanocyte proliferation, 290, 294

and melanogenesis, 320

and melanoma cell ATP levels, 370–373

in melanotroph secretoinhibition, 234

and α -MSH action mechanism, 440

MSH-dependent elevation of, 370–373, 376–377

α -MSH-induced increase of, 440, 533–535

and MSH melanogenic effect, 381

and MSH receptor binding, 383–384

in α -MSH release, 180, 188

ORG2766-induced increase of, 533–535

in pigmentation, 344

in pigment dispersion, 365

second-messenger system, 383–384, 533–535

in signal transduction pathways, 408

spinal cord cell production of, 533–535

in tyrosinase increase, 440

and voltage-activated ion currents, 215, 220, 223, 226

cAMP levels

CRF and, 240

DA effect on, 594–596

α -MSH-induced behavior and, 591–593

R-PIA reduction of, 471

UVB and, 294

CBPs, *see* Calmodulin-binding Peptides

Cerebral neurons, ebrirate uptake by, 609–610

Ciliary neurotrophic factor (CNTF), 32

Cisplatin (CPT)

in neuropathy, 406–407

neurotoxic effect of, 649–651

Cl^- current, GABA inhibition of, 564–566

CLIP, *see* Corticotropinlike intermediate lobe peptide

Congenital adrenal hyperplasia, 346

Convertases, *see* Prohormone convertases;

Proprotein convertases

Corticotropinlike intermediate lobe peptide

(CLIP), 20, 499, 585–587, 663

Corticotropin-releasing factor (CRF)
 and $[Ca^{2+}]_i$ pulsing, 240
 in cAMP level increase, 240
 in IL, 176
 MCH inhibition of, 111
 and melanotroph secretion inhibition,
 234
 and α -MSH secretion, 179
 Corticotropin-releasing hormone (CRH)
 in gonadotropin secretion, 561–563
 in melanotroph regulation, 130–132
 α -MSH regulation by, 130
 Cushing's disease, 344, 346
 Cytokines, and host responses, 418–419
 Cytosolic Ca^{2+} pulsing, *see* $[Ca^{2+}]_i$ pulsing

DA, *see* Dopamine

Diabetes mellitus
 and ACTH receptors, 542–544
 β end expression in, 539–544
 α -MSH expression in, 539–541
 neuropathy in, 404–406, 539–541
 Diazepam (DZ), and α -MSH-induced
 behavior, 591–593
 Distal retinal pigment hormone (DRPH), 79
 Dopamine (DA)
 in action potential suppression, 214–215
 in background adaptation, 486–487
 and BCT secretion, 499–500
 in Ca^{2+} channel gating, 211–226, 233–234
 Ca^{2+} current inhibition by, 199
 and $[Ca^{2+}]_i$, 232
 $[Ca^{2+}]_i$ -pulsing suppression by, 238, 606–608
 and cAMP levels, 594–596
 GABA colocalization with, 199, 486
 and HVA Ca channels, 221–226
 and JP release inhibition, 552–553
 melanocortins and, 35
 and melanotroph secretoinhibition, 130–132,
 234–235
 membrane potential modulation by, 216
 α -MSH inhibition by, 102–106, 130–131,
 176, 183, 188, 211
 NPY colocalization with, 486
 ORG 2766 and, 42
 and Parkinsonism, 41–42
 in POMC gene expression, 89, 253,
 255–257
 POMC synthesis inhibition by, 102–107
 Dopamine (DA) receptors
 in Ca^{2+} channel gating, 211–226
 in melanoma cells, 660–662
 and melanophore bioelectric currents, 212,
 219, 225
 and α -MSH release, 199
 plasticity of, 478–480

Dopaminergic neurons
 differentiation of, 505–507
 in IL histogenesis, 89
 DTPA- α -MSH
 in melanoma imaging, 451–453
 in melanoma tumor targeting, 445–447

E

Ebitride
 BBB transport of, 609–610
 and learning/memory improvement, 610
 β -Endorphin (β end)
 N-acetylated form of, 530–532
 N-acetylation of, 161–163, 165–168
 in cardiac muscle, 575–577
 expression
 in adenofibromas, 473–474
 in diabetes mellitus, 539–544
 in human breast cancer, 473–474
 IL origin of, 89
 in PBC, 454
 POMC processing and, 131–132
 processing of, 149
 role of, 246
 sex steroids and, 250
 in skeletal muscle fibers, 536–538, 542–
 544
 skeletal muscle receptors for, 542–544
 subcellular localization of, 612–614
 Epilepticlike phenomena
 ACTH/MSH neuropeptides and, 21–22
 melanotropin effect on, 23–26
 Experimental allergic neuritis (EAN)
 as Guillain-Barré model, 493
 ORG2766 protection against, 493–495
 Extracellular matrix (ECM) proteins, *see also*
 Fibronectin; Laminin
 melanocyte attachment to, 381, 549–551
 α -MSH effect on, 386–388

F

Fever, *see also* Antipyretic action
 melanotropin effect on, 25–26
 Fibroblast growth factor (FGF), *see also*
 Basic fibroblast growth factor
 in melanocyte differentiation, 292–293
 as melanocyte mitogen, 290
 in melanocyte proliferation, 293–295
 receptor kinases for, 295, 297
 and UVB effects, 293–295
 Fibronectin, melanocyte attachment to, 382,
 386–387, 549–551
 Furin, 135–139, *see also* Proprotein
 convertases
 cellular distribution of, 14, 17
 in SCLC, 16

GABA, *see* γ -Aminobutyric acid

GF, *see* Growth factors

Glucocorticoids

MCH regulation by, 121

in POMC gene expression, 248–250, 258

in POMC gene repression, 663, 668–670

Gonadotropin secretion, α -MSH-CRH

interaction and, 561–563

G proteins, in Ca^{2+} channel gating, 212–223, 225–226

Grooming, melanotropin effects on, 21–23

Growth factors (GF), 13

in adult regeneration, 37–42

antisense DNA and, 16

in CNS, 33–35

in CNS regeneration, 40–42

melanotropins as, 29–48

in neonatal regeneration, 42–46

and neoplasia, 16–18

in neuromuscular system, 36–37

perinatal effects of, 33–37

precursor PC cleavage sites, 15–16

in tissue culture, 31–32

Growth hormone (GH), MCH-induced release of, 73–74

GTP, in DA ionic channel regulation, 212–215, 220–223

Guillain-Barré syndrome model, 493–495, *see also* Experimental allergic neuritis

5-HT, *see* Serotonin

Hyperpigmentation

and adrenal insufficiency, 1

in PBC patients, 454–458

Hypothalamic α -MSH neurons

inhibitory factors of, 267–274

α -MSH-related peptides from, 261–262

α -MSH release from, 262–267

Hypothalamus

dopaminergic innervation in, 486–487

and MCH origin, 65–67

NMDA-stimulated α -MSH release from, 646–648

IL, *see* Intermediate lobe

Inositol phosphate metabolism

in background adaptation, 188–197

in melanotroph regulation, 182, 188–197

α -MSH effects on, 189, 194, 197

Interferon (IFN γ), α -MSH blockage of, 569

Interleukins (ILs)

α -MSH inhibition of, 569

in α -MSH production, 567–568

Intermediate lobe (IL), *see also* Melanotrophs

N-acetylated β end in, 530–532

development, 91–101

β end secretion in, 199

GABA receptors in, 199–201

5-HT effects in, 205–208

hypothalamic innervation of, 175–176

melanotrophic cells of, 89

melanotroph populations in, 527–529

α -MSH secretion in, 199

ontogenetic innervation of, 643–645

peptides produced in, 89

POMC gene expression in, 199

secretory pathways in, 639–641

TRH receptors in, 200

Intermediate lobe (IL) cells

$[\text{Ca}^{2+}]_i$ imaging of, 579–584

characterization of, 527–529

in DA neuron differentiation, 505–507

differentiation of, 99

POMC synthesis in, 97, 99–100, 102–103, 105–106

Intermediate lobe (IL) grafts, selective innervation of, 643–645

Joining peptide (JP), pituitary secretion of, 552–553

Keratinocytes

immunosuppressive melanotropins from, 567–570

UVB-stimulated α -MSH release from, 567

Kex, *see* Proprotein convertases

Lacrimal gland

melanocortins and, 375–376

melanotropin receptors in, 621–624

Laminin, melanocyte attachment to, 382, 386–387, 549–551

Learning, melanotropin effects on, 22–23, 25–26

Lipid membranes, melanotropic peptide interaction with, 459–461

Low-voltage activated (LVA) calcium channels, in melanotrophs, 211–212

MCH, *see* Melanin-concentrating hormone
Medial septum/diagonal band complex (MS/DBC)

functional involvements of, 462

MCH neurons in, 463–465

Melanin

MCH and, 111

α -MSH and, 111, 130, 440

in PBC, 454–455

Melanin-concentrating hormone (MCH) and ACTH release, 73, 111

- in auditory gating, 571-573
- and AVP secretion, 588-590
- bioactivity of, 72-74, 489-491
- color-change role of, 279-286
- CRF and, 111
- functional consideration of, 124-125
- function of, 448
- and GH release, 73
- in human brain, 619-620
- hypophysiotropic function of, 73-74
- hypothalamic origin of, 65-67, 70
- MCH gene, 67
- melanin-concentrating activity of, 72-73
- melanin-dispersing activity of, 73, 111
- as melanotropin, 286-288
- in MS/DBC, 462-465
- and α -MSH, 64, 70, 72-73, 571-574
- in α -MSH release, 73, 111, 286-287, 448-449
- neuromodulatory function of, 73-74
- and OT secretion, 588-590
- PC2 colocalization with, 142-144
- phylogenetic distribution of, 70-72
- and posterior pituitary function, 588-590
- precursor, 112-115
- precursor of, 112-115
- regulation
 - under chronic stress, 123-124
 - by glucocorticoids, 121-122
 - under osmotic stress, 124
- sequence analysis of, 65, 68-69
- skin melanophore regulation by, 448
- stress-related release of, 111
- structure of, 111-115
- synthesis of, 67-70, 489-491
- Melanin-concentrating hormone (MCH) gene expression
 - challenges to, 512
 - cholinergic inputs and, 514
 - insulin-induced hypoglycemia and, 512-514
- structure of, 112, 115-120
- Melanin-concentrating hormone (MCH) neurons, 511-515
- immunoreactive, 462-465
- morphofunctional studies of, 511-515
- in MS/DBC, 463-465
- ontogeny of, 514-515
- Melanin-concentrating hormone mRNA (MCHmRNA)
 - structure of, 112, 114
 - synthesis of, 116, 118-120, 122
- Melanin-concentrating hormone mRNA (MCHmRNA) expression
 - under chronic stress, 123-124
 - developmental regulation of, 121
 - glucocorticoid regulation of, 121
 - under osmotic stress, 124
- Melanin dispersion, *see also* Melanogenesis;
 - Pigment dispersion
 - MCH and, 73, 111
 - α -MSH in, 130 381, 388-389
- Melanocortin receptors
 - characterization of, 352-353
 - chromosome mapping of, 353-355
 - cloning of, 345, 347-352
 - of neural γ -MSH, 358
- Melanocortins, *see also* Melanotropins
 - and astrocyte function, 376-377
 - in CNS, 33-35
 - in CNS regeneration, 40-42
 - as GFs, 29, 31-48
 - in 5-HT neuronal development, 31, 33-35
 - and lacrimal gland, 375-376
 - in muscle atrophy, 38
 - in neonatal nerve regeneration, 42-46
 - in nerve injury recovery, 31
 - in neural development, 46-47
 - in neuromuscular system, 36-37
 - and neuron cultures, 402
 - in neuropathy therapy, 401-402, 404-408
 - neurotrophic efficacy of, 401-404
 - perinatal administration of, 37-42, 46-48
 - physiological effects of, 364
 - in PNS regeneration, 37-40
 - in postlesion neuron repair, 403-404
 - in regeneration, 46-47
 - signaling mechanisms controlled by, 364-377
 - in stressed systems, 48
 - timely administration of, 29, 31
 - in tissue culture, 31-32
- Melanocytes
 - differentiation
 - MSH in, 290-293
 - receptor kinases in, 295-298
 - ECM attachment of, 382, 549-551
 - and human skin pigmentation, 425-426, 437
 - melanogenesis regulation in, 302-303, 313-218
 - mitogens of, 290-291, 293-295
 - α -MSH effect on, 549-551
 - MSH receptor expression by, 381-389
 - nervous vs. hormonal control of, 283-286
 - proliferation
 - cAMP in, 290, 294
 - MSH in, 290-291
 - UVB in, 293-295
 - signal transduction in, 295-298
- Melanocyte-stimulating hormone (MSH), *see also* bisMSH-DPTA
 - and animal coloration, 424-425
 - assay for, 5
 - biological activities of, 342, 344, 346-348, 364-366
 - Ca²⁺ dependency of, 365

- and cAMP, 370-373, 376-377, 440
in insects, 600-602
and melanocyte-ECM attachment, 386-388
and melanogenesis, 381, 385-386, 388-389
and melanoma cell PME production, 373-375
melanoma uptake of, 394-395
related peptides
 in brain, 626-629
 characterization of, 635-637
 seasonal ovarian variations of, 502
Melanocyte-stimulating hormone (MSH)
 receptor
 Ca²⁺ dependency of, 365-367
 CBPs and, 367-369
 characterization of, 352-353
 chromosome mapping of, 353-355
 cloning of, 347-352, 358-359
 detection of, 445-447
 in human melanocytes, 381-389
 isolation of, 442-443
 on melanoma cells, 320-340, 364-370
 on melanoma tumors, 445-447
 α -MSH analogues and, 445-447
 regional ontogeny of, 652-654
 regulation of, 326-330
 structure-activity relationship, 325-326
Melanocyte-stimulating hormone (MSH)
 receptor binding, 324, 382
 cAMP second-messenger system in, 383-384
 cholera toxin effect on, 383-384
 on melanoma cells, 382-383
 TNF α effects on, 384-385
 TPA/cholera toxin effects on, 383-384
 UVB effects on, 384, 386, 388
 α -Melanocyte-stimulating hormone (α -MSH),
 see also Melanocortins; Melanotropins;
 Superpotent melanotropins
 N-acetylation of, 161-163, 165-168
 and AIDS, 418-419
 anatomical localization of, 634-635
 anti-CPT effect of, 649-651
 antiinflammatory action of, 415-416, 418
 antipyretic action of, 412-415, 418
 and attentional process, 23
 in auditory gating, 571-573
 and avoidance behavior, 20-22
 behavior induced by, 591-593
 biological effects of, 344, 346-348
 and cAMP, 440
 and cAMP levels, 533-535, 591-596
 in cardiac muscle, 575-577
 characterization of, 260-261
 CNS action of, 416
 comparative distribution of, 630-633
 CRH regulation of, 130
 as cytokine antagonist, 417-419
 DA inhibition of, 130
 in diabetes mellitus, 539-541
 distribution of, 20
 DTPA analogue of, 445-447
 and epilepticlike syndromes, 23-24
 in fish brain, 630-633
 in frog brain, 626-628
 function of, 448
 GABA agonists and, 591-593
 GABA inhibition of, 130
 in gonadotropin secretion, 561-563
 and grooming behavior, 22-23
 and host responses, 418
 human melanocyte response to, 381-382
 in hyperpigmented PBC patients, 454-458
 IFN γ inhibition by, 569
 IL origin of, 89
 IL secretion of, 199
 immunoreactivity expression, 536-538
 immunosuppressive capacity of, 569
 in insects, 600-602
 interleukins inhibition by, 569
 internalization of, 440-441
 keratinocyte production of, 567-570
 in lungfish brain, 634-637
 and MCH, 64, 70, 72-73, 571-574
 and melanin content, 440
 in melanin dispersion, 130
 and melanocyte differentiation, 290-293
 and melanocyte-ECM attachment, 382, 549-551
 and melanocyte proliferation, 290-291
 and melanogenesis, 320-321
 in melanoma tumor targeting, 445-447
 and motor function recovery, 38-39
 NDP analogue of, 597-599
 and nerve regeneration, 555-556
 in nerve repair, 655-659
 and neurite growth, 32
 and neuromuscular maturation, 29, 31
 in neuropathy treatment, 401-402, 407-408
 NPY control of, 466-469
 NPY inhibition of, 130
 photoactivable derivative of, 442-443
 as pigmentary hormone, 381, 388-389
 POMC processing and, 131-132
 and regeneration, 45
 regulation of, 102-106
 release of, 111
 in skeletal muscle fibers, 536-538
 in skin melanophore regulation, 448
 structure-activity relationships for, 53, 597-599
 structure of, 30, 51
 subcellular localization of, 612-614
 TNF α inhibition by, 569
 TRH regulation of, 130

- and tumor cell growth, 320-321
- and tyrosinase activity, 320
- α -Melanocyte-stimulating hormone (α -MSH)
 - analogues, 426-431
 - conformational study of, 517-519
 - lipid membrane interaction with, 459-461
- α -Melanocyte-stimulating hormone (α -MSH) neurons
 - GABA regulation of, 267-270
 - NPY regulation of, 270-274
- α -Melanocyte-stimulating hormone (α -MSH) release
 - ACh in, 471
 - adenosine inhibition of, 470-472
 - $[Ca^{2+}]$ in, 521-522
 - DA inhibition of, 199
 - D2 receptor activation and, 199
 - GABA receptors in, 199
 - GABA regulation of, 267-270
 - 5-HT and, 646-648
 - from hypothalamic neurons, 261-262
 - ionic dependency of, 262-267
 - MCH control of, 286-287, 448-449
 - nicotine-induced, 520-522
 - NMDA potentiation of, 646-648
 - NPY inhibition of, 466-469
 - NPY regulation of, 270-274
 - receptor mediation of, 522
 - regulation of, 130-132
- α -Melanocyte-stimulating hormone (α -MSH) secretion
 - adrenergic system effect on, 558-560
 - $[Ca^{2+}]$ in, 180-181, 188, 201
 - cAMP production and, 180, 183
 - control of, 176-179
 - CRF and, 176, 179
 - DA and, 176, 183, 188, 211
 - GABA and, 176-178, 183, 188
 - 5-HT inhibition of, 176, 179
 - hypothalamic regulation of, 175-179
 - $[K^+]$ and, 230
 - mesotocin and, 176
 - molecular aspects of, 180-183
 - neurotransmitters and, 176-180, 188
 - NPY inhibition of, 176-177, 179-180, 183
 - TRH and, 176, 179-183, 471, 527-529
 - voltage-dependent Ca^{2+} channels and, 201
- β -Melanocyte-stimulating hormone (β -MSH), 13, 29, 364-365, *see also* Melanocortins; Melanotropins and attentional processes, 23
- effects of, 344
- in insects, 602-603
- in melanocyte proliferation, 290-291
- melanoma cell response to, 370
- and melanoma cell targeting, 391
- sequence of, 7
- γ -Melanocyte-stimulating hormone (γ -MSH), 20, 365, *see also* Melanocortins; Melanotropins
 - in frog brain, 626-628
 - and melanocortin receptor, 358
 - natriuretic actions of, 545-547
- Melanogenesis
 - cAMP and, 320, 381, 383-384
 - hormonal regulation of, 302-318
 - melanocyte-ECM attachment and, 382, 549-551
 - α -MSH effect on, 320-321, 381, 385-386
 - tyrosinase and, 321, 381
 - UVB and, 381, 384-386, 388
- Melanoma cells
 - ATP depletion in, 370-373
 - bFGF in, 292
 - CBPs in, 367-369
 - DA receptor mRNA in, 660-662
 - melanogenesis in, 381
 - melpalan-peptides cytotoxicity toward, 616-618
 - α -MSH binding on, 440-441
 - MSH receptors on, 320-340, 365-370
 - MSH-UVB interaction effect on, 381, 384, 386
 - PME levels in, 371-375
 - targeting
 - DTPA-MSH in, 445-447, 451-453
 - β -MSH in, 391
 - α -MSH-melpalan in, 391-399
 - MSH-receptor in, 394-399
- Melanophores, *see* Melanocytes
- Melanostatin, *see* Neuropeptide Y
- Melanotrophs
 - action potential in, 211, 230
 - adenosine action on, 470-472
 - autonomous secretion in, 231-241
 - in background adaptation, 639
 - cytosolic $[Ca^{2+}]$ in, 606-608
 - dopaminergic secretoinhibition of, 234-235
 - electrical activity in, 211-212
 - factors controlling activity of, 130-132
 - GABA-induced Cl^- current in, 564-566
 - hormonal regulation of, 175-183
 - in IL, 89, 527-529
 - inositol phosphate regulation of, 188-197
 - ionic channel gating in, 211-212
 - LVA Ca^{2+} channels in, 211-212
 - morphofunctional aspects of, 91-108
 - α -MSH/ β end in, 612-613
 - neuropeptide control of, 176-180
 - nicotine-induced α -MSH release by, 520-522
 - pH imaging of, 579-584
 - POMC synthesis in, 175
 - secretion by, 211

- secretoinhibitory innervation of, 238
 spontaneous $[Ca^{2+}]$ pulsing in, 603-608
 Melanotropic peptides, 342-345, *see also*
 Melanocortins
 and ACTH release, 483-484
 for cosmetic skin tanning, 432-434
 delivery routes of, 436-437
 effects of, 346-347
 in fish ovary, 502-504
 and human skin pigmentation, 425-426, 437
 in insects, 600-602
 lipid membrane interaction with, 459-461
 multiple actions of, 448-450
 protective pigmentation role of, 434
 receptors for, 347-359
 second generation, 436
 for therapeutic tanning, 434
 Melanotropins, *see also* Melanocortins;
 Superpotent melanotropins
 in adult regeneration, 37-40
 alternate delivery routes of, 436-437
 antipyretic effects of, 25-26
 and behavior, 22-26
 brain receptors for, 621-624
 and epilepticlike syndromes, 23-25
 formation of, 20-21, 29
 as GFs, 29-48
 and grooming behavior, 23
 keratinocyte production of, 567-570
 and learning, 22-23, 25-26
 and muscle atrophy prevention, 38
 in neonatal regeneration, 42, 45-46
 in nerve regeneration, 47
 in neuromuscular system development,
 46-47
 as neuropeptides, 20-26
 perinatal administration of, 46
 and social behavior, 24-25
 and stretching-yawning syndrome, 23
 synthetic analogues of, 426-431
 transdermal delivery of, 431-432
 Melphalan- α -MSH
 anti-melanoma cell toxicity of, 616-618
 design of, 391-394
 in melanoma therapy, 395-399
 in melanoma treatment, 391, 394-400
 preclinical studies on, 394
 Membrane potential, *see also* Action potential
 in Ca^{2+} channel regulation, 212-221
 DA modulation of, 216
 MS/DBC, *see* Medial septum/diagonal band
 complex
 MSH, *see* Melanocyte-stimulating hormone
 NDP-MSH, *see* Nle^bPhe^2 - α -MSH
 NEI, *see* Neuropeptide-E-I
 Neoplasia
 GFs and, 16-18
 opioid peptides in, 473-474
 PCs and, 16-18
 Nerve growth factor (NGF), 15, 32, 34
 Nerve regeneration
 ACTH analogues and, 38-42, 47
 ACTH in, 31, 403-404
 ACTH/MSH peptides and, 31, 33-36,
 38-40, 45-47
 adult, 37-42
 bFGF and, 555-556
 in CNS, 31, 33-36, 40-42
 factors involved in, 40-46
 GFs in, 33-36
 melanocortins in, 37-45
 morphological/metabolic parameters of,
 45-48
 α -MSH and, 38-41, 45-47, 555-556
 MSH peptides and, 31, 33-36, 38-40,
 45-47
 neonatal, 42, 45-46
 in neuromuscular system, 29-31, 36-37
 peripheral, 31, 37-40
 Neural γ -MSH receptors, *see* MSH receptors
 Neurite growth
 ACTH analogues and, 32
 NGF and, 34
 Neuromuscular system
 ACTH peptides and, 35-37
 development of, 35-36
 melanocortins and, 29-31
 perinatal melanocortin administration and,
 37-42, 46-48
 regeneration in, 29
 Neuropathy
 ACTH treatment for, 401-402, 405-408
 cisplatin, 406-407
 diabetes mellitus and, 404-406, 539-541
 melanocortin treatment for, 401-403,
 407-408
 melanotropin treatment potential in,
 401-408
 Neuropeptide-E-I (NEI), and posterior
 pituitary function, 588-590
 Neuropeptides, *see also* Melanocortins;
 Melanotropins
 and behavior, 20-26
 Neuropeptide Y (NPY)
 in Ca^{2+} channel inhibition, 274
 in $[Ca^{2+}]$ -pulsing suppression, 238, 606-608
 DA colocalization with, 486
 GABA colocalization with, 177, 486
 and hypothalamic CRF decrease, 468
 in melanotroph secretoinhibition, 130-132,
 176, 234-235
 α -MSH inhibition by, 130
 in α -MSH neuron regulation, 270-274
 in α -MSH release, 179-180, 183, 466-469
 regulatory functions of, 466
 NGF, *see* Nerve growth factor

Nle⁴D¹Phe⁷- α -MSH (NDP-MSH), *see also*

- Superpotent melanotropins
- binding site ontogeny, 652-654
- biological activity of, 60-61
- in cytotoxicity studies, 616-618
- and grooming behavior, 21-22
- melanocyte responsiveness to, 385-386
- and melanotropin receptors, 621-624
- potency of, 54, 57-58
- and receptor binding, 382-385
- and skin darkening, 381
- structure-activity relationships of, 597-599
- and tyrosinase activity, 313, 320

NMDA, in hypothalamic α -MSH release, 646-648

ORG2766

- anti-CPT effect of, 651
- behavioral effects of, 22-25
- in cAMP increase, 533-535
- and DA uptake, 42
- in EAN protection, 493-495
- and motor function recovery, 41
- and neurite growth, 32, 34, 46-47, 402
- and neuromuscular maturation, 29, 31
- in Parkinsonism treatment, 40-41
- POMC processing and, 29
- and postlesion neuron repair, 403, 405-407
- and Schwann cell binding specificity, 496-498
- and spontaneous nystagmus compensation, 524-526
- structure of, 30

Oxytocin (OT) secretion, MCH/NEI action on, 588-590

PACE4, *see* Proprotein convertases

PAM, *see* Peptidylglycine α -amidating monooxygenase

Parkinsonism, 41-42

PBC, *see* Primary biliary cirrhosis

PC, *see* Proprotein convertases

PDH, *see* Pigment dispersing hormone

Peptidylglycine α -amidating monooxygenase (PAM)

- cleavage consequences, 155-157
- and POMC processing, 149-151
- posttranslational processing of, 151-155
- and processing enzymes, 147-155

pH imaging, 579-584

Pigment-dispersing hormone (PDH)

- analogue potencies, 82-83
- chemistry of, 79-80
- immunodetection of, 83-85
- and insect AKHs, 78-79
- and insect pigment dispersing factors, 80-86
- structure-activity relationships of, 81-83

Pigment dispersion, *see also* Melanin dispersion

cAMP in, 365

Pituitary primordia, morphological features of, 91-92

POMC, *see* Proopiomelanocortin

Posterior pituitary function

MCH effects on, 588-590

NEI effects on, 588-590

Potassium channels, in Ca^{2+} channel gating, 212-219

Primary biliary cirrhosis (PBC)

hyperpigmentation in, 454-458

α -MSH plasma levels in, 454-458

Processing enzymes

α -amidation by, 147-149

and POMC, 149-151

posttranslational processing of, 151-155

Prohormone convertases (PC), 135-144,

147-155

Pronerve growth factor- β (proNGF- β), 15

Proopiomelanocortin (POMC), 13, 18, 51

α -amidation of, 147

bioactivity of, 246

derivatives of, 89, 111, 344-347, 575-577, 612-614, *see also* Proopiomelanocortin peptides

distribution of, 20-21

expression of, 508-510

melanocortin derivatives of, 364-365

melanotrope synthesis of, 188

melanotrophs and, 175

and melanotropins, 29

as α -MSH precursor, 161-172, 175, 188

in PNS development, 403-404

production sites, 567

subcellular localization of, 612-614

Proopiomelanocortin (POMC) gene

cell-specific transcription of, 663-668

cloning of, 476-477

DA inhibition of, 131

GABA inhibition of, 131

glucocorticoid repression of, 663, 668-669

hormone-dependent repression of, 670

NPY inhibition of, 131

products of, 246

transcription regulation, 663-666

Proopiomelanocortin (POMC) gene expression

DA regulation of, 89, 253-258

GABA control of, 89

glucocorticoid regulation of, 248-250, 258

ontogenesis of, 92, 94-100

sex steroid regulation of, 250-253, 258, 477

Proopiomelanocortin (POMC) mRNA

cardiac muscle expression of, 575-577

photostimuli and, 131

testosterone-induced increase in, 477

Proopiomelanocortin (POMC) peptides,

20-22, 161-163

- N*-acetylation of, 161–163, 612–614
 in diabetes mellitus, 539–541
 expression of, 508–510, 575–577
 localization of, 95–97
 release of, 639–641
- Proopiomelanocortin (POMC) processing,
 260–261, 343
 to ACTH, 149–151
 in cardiac muscle, 575–577
 and β end, 149
 to β end, 131–132
 in IL, 585–587
 and α -MSH, 131–132, 147, 149–151
 by PCs, 139–140, 147–151
 products of, 20–22, 161–163
- Proopiomelanocortin (POMC) synthesis
N-acetylation mechanism in, 161–163
 DA inhibition of, 102–107, 224
 phylogenetic perspectives of, 161–172
- Proprotein convertases (PC), 13, 135–136
 and cell proliferation, 17–18
 cleavage sites of, 15–16
 cleavage specificity of, 139–141
 comparative structures of, 136–138
 GF role of, 14–15
 localization of, 141–142
 MCH colocalization with, 142–144
 and neoplasia, 16–18
 PAM and, 147
 similarities/dissimilarities among, 14–15
 subcellular location of, 14, 17
 subtilisinlike, 136–138
- R**eceptor kinases
 in melanocyte differentiation, 295–298
 and signal transduction, 295–298
- Red pigment concentrating hormone (RPCH),
 78–79
 and AKH, 80
 secretory path association with, 85
- Regeneration, *see* Nerve regeneration
- Rotational behavior, 42
- S**CLC, *see* Small cell lung carcinoma
- Second-messenger systems
 in Ca^{2+} channel gating control, 219–221,
 224–225
 cAMP, 383–384, 533–535
 in K^+ channels, 219
 in Na^+ channels, 220–221
- Serotonin (5-HT)
 ACTH peptide modulation of, 31, 33–35
 and Ca^{2+} currents, 200, 205–207
 and hypothalamic α -MSH release, 646–648
 in IL, 200, 205
 neuronal development, 33
- Sex steroids
 β end-level modulation by, 250
 in POMC gene expression, 477
 in POMC mRNA regulation, 250–253, 258
- Sexual behavior, perinatal melanocortin
 treatment and, 33
- Signaling mechanisms
 in astrocytes, 376–377
 in lacrimal gland, 375–376
 in melanoma, 365–375
- Signal transduction, and receptor kinases,
 295–298
- Skin pigmentation
 and cosmetic/therapeutic tanning, 432–434
 melanocytes and, 425–426
 protective role of, 434
- Small cell lung carcinoma (SCLC), PCs in
 Social behavior, melanotropin effects
 on, 24–25
- Sodium channels
 in Ca^{2+} channel gating, 219–221
 second-messenger system in, 220–221
 TRH regulation of, 220
- Spontaneous calcium entry hypothesis
 events leading to, 229–231
 evidence for, 231–242
- Spontaneous nystagmus, compensation of,
 524–526
- Stretching
 ACTH/MSH neuropeptides and, 22
 melanotropin effect on, 23
- Subtilisinlike proteinases, *see* Proprotein
 convertases
- Superpotent melanotropins, 51–61, 430, *see*
also NDP- α -MSH
 biological activities of, 52–53, 60–61
 potencies of, 54–55, 57–61
 structure of, 51, 53–61, 430
 synthesis of, 52
- T**etrodotoxin (TTX)
 Na^+ spike elimination by, 231
 and “resting” membrane potential, 229–232
- Thyrotropin-releasing hormone (TRH) in
 action potential acceleration, 230
 in Ca^{2+} release, 201–202
 and GH_3 cell secretion, 229–230
 in IL cells, 199
 in JP secretion, 552–553
 in melanotroph secretory response,
 130–132, 234, 527–529
 mesotocin colocalization with, 176
 in α -MSH release, 130, 176, 179–183, 471,
 527–529
 in Na^+ channel regulation, 220
- Tyrosinase
 cAMP and, 440

in melanocytes, 295-298
and melanogenesis, 321, 381
regulation of, 313-318
Tyrosinase activity
dopaminergic regulation of, 505-506
 α -MSH effect on, 321, 440-441
NDP-MSH effect on, 313, 320

Ultraviolet B (UVB) light
and intracellular cAMP levels, 294

in keratinocyte α -MSH release, 567
and melanocyte mitogens, 293-295
in melanocyte proliferation, 293-295
and melanogenesis, 386
and MSH-receptor binding, 381-386, 388

Yawning
ACTH/MSH neuropeptides and, 22
melanotropin effect on, 23